InvestorQ : Can you throw some light on the Redyx recently launched by Reddy labs?
Debbie Mascarenhas made post

Can you throw some light on the Redyx recently launched by Reddy labs?

Answer
user profile image
Arti Chavan answered.
3 weeks ago


Reddy Labs launched a generic version of Remdesivir, licensed to the company by Gilead Inc of the United States. Remdesivir is used in the treatment of advanced stages of COVID-19. This is unlike Favipiravir which is used for more mild symptoms of COVID-19.

Reddy Labs has just launched Remdesivir generic in India under the brand name Redyx in India. The DCGI approved Remdesivir for restricted emergency use only for COVID-19 patients hospitalised with very severe symptoms of the affliction.

The licensing agreement with Gilead gives Reddy Labs the rights to manufacture and sell Remdesivir in 127 countries, including India. Apart from Reddy Labs, there are other Indian pharma companies like Cipla and Jubilant Life that are also licensed.

Redyx will be made available in strength of 100 mg vial. Reddy Labs has been licensed by Gilead to sell Remdesivir under USFDA emergency approval. That allows manufacture and sale of these drugs without royalty fees only for the specific emergency period.